- Home
- TYRA vs NRIM Comparison
TYRA vs NRIM Comparison
Compare TYRA & NRIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- NRIM
- Stock Information
- Founded
- TYRA 2018
- NRIM 1990
- Country
- TYRA United States
- NRIM United States
- Employees
- TYRA N/A
- NRIM N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- NRIM Savings Institutions
- Sector
- TYRA Health Care
- NRIM Finance
- Exchange
- TYRA Nasdaq
- NRIM Nasdaq
- Market Cap
- TYRA 576.6M
- NRIM 514.9M
- IPO Year
- TYRA 2021
- NRIM N/A
- Fundamental
- Price
- TYRA $10.47
- NRIM $94.71
- Analyst Decision
- TYRA Strong Buy
- NRIM
- Analyst Count
- TYRA 7
- NRIM 0
- Target Price
- TYRA $30.86
- NRIM N/A
- AVG Volume (30 Days)
- TYRA 364.1K
- NRIM 72.9K
- Earning Date
- TYRA 08-06-2025
- NRIM 07-23-2025
- Dividend Yield
- TYRA N/A
- NRIM 2.65%
- EPS Growth
- TYRA N/A
- NRIM 46.48
- EPS
- TYRA N/A
- NRIM 7.52
- Revenue
- TYRA N/A
- NRIM $164,695,000.00
- Revenue This Year
- TYRA N/A
- NRIM N/A
- Revenue Next Year
- TYRA N/A
- NRIM $7.05
- P/E Ratio
- TYRA N/A
- NRIM $12.85
- Revenue Growth
- TYRA N/A
- NRIM 26.35
- 52 Week Low
- TYRA $6.42
- NRIM $57.00
- 52 Week High
- TYRA $29.60
- NRIM $100.21
- Technical
- Relative Strength Index (RSI)
- TYRA 58.12
- NRIM 56.53
- Support Level
- TYRA $9.93
- NRIM $96.01
- Resistance Level
- TYRA $10.49
- NRIM $100.21
- Average True Range (ATR)
- TYRA 0.59
- NRIM 2.39
- MACD
- TYRA 0.08
- NRIM 0.07
- Stochastic Oscillator
- TYRA 94.30
- NRIM 61.16
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.